Oguri T, Fujiwara Y, Ochiai M, Fujitaka K, Miyazaki M, Takahashi T, Yokozaki M, Isobe T, Ohune T, Tsuya T, Katoh O, Yamakido M
Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Anticancer Res. 1998 Nov-Dec;18(6A):4159-62.
Platinum drug resistance is an important problem in lung cancer chemotherapy. In this study, we examined lung-resistance protein (LRP) gene expression in vivo and in vitro in relation to platinum drug exposure.
The expression levels of the LRP gene were assessed by the reverse transcription polymerase chain reaction, in 80 autopsy samples (40 lung tumors and 40 corresponding normal lung tissues), two lung cancer cell lines and in peripheral mononuclear cells collected from 8 lung cancer patients before and after platinum drug administration.
The LRP gene expression levels of autopsy specimens exposed antemortem to platinum drugs were not significantly different to those of specimens without platinum drug exposure, for both lung tumors and normal lung tissues. Our results also demonstrate that LRP gene expression was not induced by platinum drugs either in vitro or in vivo.
The present results indicate that LRP gene expression is not associated with platinum drug exposure in lung cancer.
铂类药物耐药是肺癌化疗中的一个重要问题。在本研究中,我们检测了体内和体外肺耐药蛋白(LRP)基因表达与铂类药物暴露的关系。
通过逆转录聚合酶链反应评估80份尸检样本(40份肺肿瘤组织和40份相应的正常肺组织)、两种肺癌细胞系以及8例肺癌患者铂类药物给药前后采集的外周血单个核细胞中LRP基因的表达水平。
生前暴露于铂类药物的尸检标本中,肺肿瘤组织和正常肺组织的LRP基因表达水平与未暴露于铂类药物的标本相比,差异无统计学意义。我们的结果还表明,铂类药物在体内和体外均未诱导LRP基因表达。
目前的结果表明,肺癌中LRP基因表达与铂类药物暴露无关。